The webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A ...
Stifel analyst James Condulis tells investors that the move lower in Fulcrum Therapeutics (FULC) this morning “surprises us” ...
Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―― 20 mg ...
Fulcrum Therapeutics (NASDAQ:FULC) shared full 12-week results from the 20-mg cohort of its phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease, expanding on partial data ...
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease ...
Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare ...
Fulcrum Therapeutics (NASDAQ:FULC) fell ~10% on Tuesday after the company posted data from a late-stage study of its lead candidate, Pociredir, in sickle cell disease, along with second quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results